À¦°óSMÉçÇø

Event

Management of Disease Modifying Interventions in Alzheimer's

Tuesday, December 3, 2024 13:00to16:15
Montreal Neurological Institute de Grandpre Communications Centre, 3801 rue University, Montreal, QC, H3A 2B4, CA

This workshop will serve to discuss the indications and, prescription, and management of adverse events associated with anti-amyloid therapy with monoclonal anti-bodies.



Suzanne Schindler, MD, PhD

Department of Neurology, Washington University School of Medicine

°Õ²¹±ô°ì:ÌýBiomarkers for Detection of AD and Indications of Anti-Amyloid Therapy

Abstract: TBD


Alireza Atri, MD, PhD

Department of Neurology, Harvard Medical School

°Õ²¹±ô°ì:ÌýAmyloid Related Imaging Abnormalities (ARIA)

Abstract: TBD

Ìý

Programme

Tuesday, December 3, 2024

1:00

Welcome &ÌýOpening Remarks

Pedro Rosa-Neto, MD, PhD, The Douglas Research Centre, À¦°óSMÉçÇø

Moderator:ÌýSerge Gauthier, MD,ÌýThe Douglas Research Centre, À¦°óSMÉçÇø

1:15

Biomarkers for Detection of AD and Indications of Anti-Amyloid Therapy

Suzanne Schindler, MD, PhD,ÌýKnight Alzheimer Disease Research Center,ÌýWashington University School of Medicine in St. Louis

2:15 Refreshment Pause
2:45

Amyloid Related Imaging Abnormalities (ARIA)

Alireza Atri, MD, PhD,ÌýBanner Sun Health Research Institute,ÌýHarvard Medical School

3:45

Closing Remarks

Pedro Rosa-Neto, MD, PhD, The Douglas Research Centre, À¦°óSMÉçÇø

4:00 Cocktail & Networking

Sponsors

Logo for Eisai

Logo for Lilly

Logo for Roche

Organizing Committee

Pedro Rosa-Neto
Director, Translational Neuroimaging Laboratory, Douglas Research Centre

Debbie Rashcovsky
Neuro Events Team Lead

Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý

The Neuro logoÀ¦°óSMÉçÇø logo

Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý

Back to top